Synopsis

Thorax

Volumn 56, Issue SUPPL. 4, 2001, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; BACTERIAL ANTIGEN; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME; CLARITHROMYCIN; ERYTHROMYCIN; INFLUENZA VACCINE; LEVOFLOXACIN; PENICILLIN G; PNEUMOCOCCUS VACCINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL PNEUMONIA; BLOOD CULTURE; CHLAMYDOPHILA PSITTACI; CLINICAL FEATURE; COXIELLA BURNETII; DISEASE PREDISPOSITION; DISEASE SEVERITY; GRAM STAINING; HOME CARE; HOSPITAL CARE; HUMAN; INFLUENZA; LEGIONELLA; MEDICAL SOCIETY; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; MYCOPLASMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SERODIAGNOSIS; SPUTUM CULTURE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; THORAX RADIOGRAPHY; UNITED KINGDOM;

EID: 0035191682     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (399)

1. British thoracic society guidelines for the management of community-acquired pneumonia in adults admitted to hospital
2. Practice guidelines for the management of community-acquired pneumonia in adults
3. Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, and initial antimicrobial therapy
4. Canadian guidelines for the initial management of community-acquired pneumonia: An evidence-based update by the Canadian infectious diseases society and the Canadian thoracic society
5. Infections des voies respiratoires. Conference de consensus en therpeutique anti-infectieuse
6. Guidelines for the management of community acquired pneumonia in adults
7. Management of community acquired pneumonia in the era of pneumococcal resistance: A report from the drug resistant streptococcus pneumoniae therapeutics working group
8. Management of adult community acquired lower respiratory infections
9. Guidelines for the management of adults with community acquired pneumonia
10. An overview of community acquired pneumonia with lessons learned from the British thoracic society study
11. Hospital study of adult community-acquired pneumonia
12. Causes of pneumonia presenting to a district general hospital
13. A hospital study of community acquired pneumonia in the elderly
14. Community-acquired pneumonia in adults in UK hospitals in 1982-1983: A survey of aetiology, mortality, prognostic factors and outcome
15. Adult community-acquired pneumonia in central London
16. Increased risk of diarrhoea caused by Clostridium difficile in elderly patients receiving cefotaxime
17. Hospital-acquired Clostridium difficile diarrhoea and herd immunity
18. Successful control of Clostridium difficile infection in an elderly care unit through use of a restrictive antibiotic policy
19. Outcome of pneumonia in the elderly: A hospital survey
20. Early management of younger adults dying of community acquired pneumonia
21. Aetiology and outcome of severe community-acquired pneumonia
22. Impact of management guidelines on the outcome of severe community acquired pneumonia
23. Nosocomial lower respiratory tract infections on surgical wards
24. Aetiology of community-acquired pneumonia: A prospective study among adults requiring admission to hospital
25. Incidence of community-acquired pneumonia and Chlamydia pneumoniae infection: A prospective multicentre study
26. Chlamydia pneumoniae as a cause of community-acquired pneumonia in hospitalized patients in Berlin
27. Treatment of community-acquired pneumonia: A randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin
28. Multiple pathogens in adult patients admitted with community-acquired pneumonia: A one year prospective study of 346 consecutive patients
29. Ambulatory patients with community-acquired pneumonia: The frequency of atypical agents and clinical course
30. Guidelines and the management of community acquired pneumonia
31. Contemporary use of antibiotics in 1089 adults presenting with acute lower respiratory tract illness in general practice in the UK: Implications for developing management guidelines
32. Are junior doctors confident about prescribing for adults with lower respiratory tract illness?
33. Empirical treatment of nonsevere community acquired pneumonia: Still a difficult issue
34. Antibiotic resistance: An increasing problem? It always has been there, but there are things we can do
35. Lower respiratory tract infection and pneumonia in the community
36. Guidelines for the management of chronic obstructive pulmonary disease
37. Prospective study of the aetiology and outcome of pneumonia in the community
38. The diagnosis of adult pneumonia in general practice. The diagnostic value of history, physical examination and some blood tests
39. Prediction of pneumonia in outpatients with acute cough: A statistical approach
40. Community-acquired pneumonia requiring hospitalization: 5-Year prospective study
41. North of England evidence based guidelines development project: Methods of guideline development
42. Keeping patients informed about their illness: Community acquired pneumonia
43. Local antibiotic guidelines for adult community-acquired pneumonia: A survey of UK hospital practice in 1999
44. Choosing the best research design for each question
45. Bias in analytic research
46. User's guides to the medical literature III. How to use an article about a diagnostic test: Are the results of the study valid?
47. User's guides to the medical literature. IX. A method for grading health care recommendations
48. Medical outcomes and antimicrobial costs with the use of the American thoracic society guidelines for outpatients with community-acquired pneumonia
49. Variations in anti-microbial use and cost in more than 2,000 patients with community-acquired pneumonia
50. Use of indicators to evaluate the quality of community acquired pneumonia management
51. Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland
52. Rates of pneumonia during influenza epidemics in Seattle, 1964 to 1975
53. Prospective study of aetiology and outcome of adult lower respiratory tract infections in the community
54. Epidemiology of community-acquired pneumonia in the elderly
55. Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance study in Ohio
56. Hospitalized pneumonia. Outcomes, treatment patterns, and costs in urban and rural areas
57. Community-acquired pneumonia: The annual cost to the National Health Service in the United Kingdom
58. Viral and mycoplasmal pneumonia in a prepaid medical care group during an eight-year period
59. Patients hospitalized after initial outpatient treatment for community acquired pneumonia
60. The aetiology, management and outcome of severe community-acquired pneumonia on the intensive care unit
61. Severe community-acquired pneumonia. Epidemiology and prognostic factors
62. Management of pneumonia in the outpatient setting
63. SCAPA: Study of Community Acquired Pneumonia Aetiology in adults admitted to hospital: Implications for management guidelines
64. Community acquired pneumonia: Aetiology and prognostic index evaluation
65. Community acquired pneumonia: Aetiology and usefulness of severity criteria on admission
66. A prospective hospital study of the aetiology of community-acquired pneumonia
67. The outcome of community acquired pneumonia treated on the intensive care unit
68. Severe community-acquired pneumonia in intensive care units: Prospective validation of a prognostic score
69. Severe community-acquired neumonia. Etiology, epidemiology, and prognosis factors
70. The cost of treating community-acquired pneumonia
71. Etiology of community-acquired pneumonia: Impact of age, comorbidity, and severity
72. Prospective study on the etiology of community-acquired pneumonia in children and adults in Spain
73. Community-acquired pneumonia in adults: A multicentric observational AIPO study
74. Effect of hospital-acquired ventilator-associated pneumonia on mortality of severe community-acquired pneumonia
75. Etiology of community-acquired pneumonia: Evaluation by transtracheal aspiration, blood culture, or serology
76. Community-acquired pneumonia in chronic obstructive pulmonary disease: A Spanish multicenter study
77. Bacteraemic pneumococcal pneumonia: A continuously evolving disease
78. Nursing home-acquired pneumonia. A case-control study
79. Differences in etiology of pneumonias in nursing home and community patients
80. Pneumonia in a nursing home
81. Community-acquired aspiration pneumonia in intensive care units. Epidemiological and prognosis data
82. Comparative study of the clinical presentation of legionella pneumonia and other community-acquired pneumonias
83. Legionellosis
84. Is penicillin G an adequate initial treatment for aspiration pneumonia? A prospective evaluation using a protected specimen brush and quantitative cultures
85. Association of invasive pneumococcal disease with season, atmospheric conditions, air pollution, and the isolation of respiratory viruses
86. An outbreak of pneumococcal pneumonia in two men's shelters
87. An epidemic of pneumococcal disease in an overcrowded, inadequately ventilated jail
88. Aetiology and outcome of severe community-acquired pneumonia in Singapore
89. A prospective study of community-acquired pneumonia in Hong Kong
90. Legionnaires' disease surveillance: England and Wales, 1993
91. Legionnaires' disease surveillance: England and Wales 1994
92. Legionnaires' disease surveillance: England and Wales, 1995
93. Legionnaires' disease in residents of England and Wales: 1996
94. Legionnaires' disease in residents of England and Wales: 1998
95. Acute respiratory infections, and influenza vaccine for 1999/2000
96. An epidemic of mild pneumonia due to an unusual strain of Chlamydia psittaci
97. Epidemics of pneumonia caused by TWAR, a new Chlamydia organism, in military trainees in Finland
98. Chlamydia pneumoniae as a new source of infectious outbreaks in nursing homes
99. Clinical picture of community-acquired Chlamydia pneumoniae pneumonia requiring hospital treatment: A comparison between chlamydial and pneumococcal pneumonia
100. Chlamydial infection of the respiratory tract
101. Epidemiological features of Coxiella burnetii infection in England and Wales: 1984 to 1994
102. Influenza surveillance in England and Wales: October 1995 to June 1996
103. What are the complications of influenza and can they be prevented? Experience from the 1989 epidemic of H3N2 influenza A in general practice
104. Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination
105. Reliability of eliciting physical signs in examination of the chest
106. Pneumonia in the elderly
107. New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases
108. Prediction of microbial aetiology at admission to hospital for pneumonia from the presenting clinical features
109. Community-acquired pneumonia in the elderly. Clinical and nutritional aspects
110. Early recognition of Streptococcus pneumoniae in patients with community-acquired pneumonia
111. Mycoplasma pneumoniae pneumonia requiring hospitalization, with emphasis on infection in the elderly
112. Comparative features of pneumococcal, mycoplasmal, and Legionnaires' disease pneumonias
113. An outbreak of community-acquired Legionnaires' disease pneumonia
114. Legionella species community-acquired pneumonia. A review of 56 hospitalized adult patients
115. Pneumonia due to Legionella pneumophila and pneumococcal pneumonia: Similarities and differences on presentation
116. Legionella pneumophila. A cause of severe community-acquired pneumonia
117. Chlamydia pneumoniae community-acquired pneumonia: A review of 62 hospitalized adult patients
118. Clinical characteristics of Chlamydia pneumoniae infection as the sole cause of community-acquired pneumonia
119. Q-fever pneumonia in the Negev region of Israel: A review of 20 patients hospitalised over a period of one year
120. Importance of Q fever in community acquired pneumonia
121. Acute Q fever pneumonia: A review of 80 hospitalized patients
122. Q fever pneumonia: A review of 164 community-acquired cases in the Basque country
123. Comparison of bacteraemic community-acquired lobar pneumonia due to Streptococcus pneumoniae and Klebsiella pneumoniae in an intensive care unit
124. Community-acquired acinetobacter pneumonia
125. Streptococcus milleri liver abscess presenting as fulminant pneumonia
126. Does primary Streptococcus viridans pneumonia exist?
127. Influence of age on symptoms at presentation in patients with community-acquired pneumonia
128. Community-acquired pneumonia requiring hospitalization. Is it different in the elderly?
129. A comparison of nursing home-acquired pneumonia patients with patients with community-acquired pneumonia and nursing home patients without pneumonia
130. Comparative radiographic features of community acquired Legionnaires' disease, pneumococcal pneumonia, mycoplasma pneumonia, and psittacosis
131. Acute community-acquired pneumonias
132. Roentgenographic findings of pneumonia caused by Chlamydia pneumoniae. A comparison with streptococcus pneumonia
133. Q fever pneumonia: Appearance on chest radiographs
134. Radiographic features of staphylococcal pneumonia in adults and children
135. Klebsiella pneumonia in the modern era: Clinicoradiographic correlations
136. High resolution CT findings in community-acquired pneumonia
137. High-resolution computed tomography for the diagnosis of community-acquired pneumonia
138. Mycoplasma pneumoniae pneumonia: Radiographic and high-resolution CT features in 28 patients
139. Utilization of computed tomography in patients hospitalized with community-acquired pneumonia
140. Radiographic resolution of community-acquired pneumonia
141. The radiographic resolution of Streptococcus pneumoniae pneumonia
142. Chest radiographs in patients with community-acquired pneumonia
143. Association of pneumonia and lung cancer: The value of convalescent chest radiography and follow-up
144. A prospective audit of the value of fibreoptic bronchoscopy in adults admitted with community acquired pneumonia
145. Rapid aetiological diagnosis of pneumonia based on routine laboratory features
146. C-reactive protein. A clinical marker in community-acquired pneumonia
147. Sequential changes of inflammatory and nutritional markers in patients with community-acquired pneumonia
148. Diagnostic and prognostic value of interleukin-6 and C-reactive protein in community-acquired pneumonia
149. Initial microbiologic studies did not affect outcome in adults hospitalized with community-acquired pneumonia
150. Value of the polymerase chain reaction assay in noninvasive respiratory samples for diagnosis of community-acquired pneumonia
151. Value of routine microbial investigation in community-acquired pneumonia treated in a tertiary care center
152. The value of routine microbial investigation in community-acquired pneumonia
153. Observations from a multicentre study on the use of the sputum specimen in patients hospitalized with community-acquired pneumonia
154. Sputum Gram's stain in community-acquired pneumococcal pneumonia. A meta-analysis
155. Accuracy of Gram's stain in identifying pneumococci in sputum
156. Evaluation of housestaff physicians' preparation and interpretation of sputum Gram stains for community-acquired pneumonia
157. Utility of Gram's stain and efficacy of quantitative cultures for post-traumatic pneumonia: A prospective study
158. Role of pneumococcal antigen in the diagnosis of pneumococcal pneumonia
159. Antigen detection in pneumococcal pneumonia
160. Measurement of antibody responses to pneumolysin: A promising method for the presumptive aetiological diagnosis of pneumococcal pneumonia
161. Evaluation of urinary antigen ELISA for diagnosing Legionella pneumophila serogroup 1 infection
162. False-positive legionella titres in routine clinical serology testing detected by absorption with campylobacter: Implications for the serological diagnosis of legionnaires' disease
163. Mycoplasma pneumoniae antibody assays
164. The differentiation of Chlamydia species by antigen detection in sputum specimens from patients with community-acquired acute respiratory infections
165. Comparison of throat swabs with sputum specimens for the detection of Chlamydia pneumoniae antigen by direct immunofluorescence
166. Rapid diagnosis of respiratory Chlamydia pneumoniae infection by nested touchdown polymerase chain reaction compared with culture and antigen detection by EIA
167. Chlamydial respiratory infections. Don't get bogged down by differentiating species
168. Evaluation of Chlamydia immunoglobulin M (IgM), IgG, and IgA rELI-SAs Medac for diagnosis of Chlamydia pneumoniae infection
169. Severe community-acquired pneumonia. Assessment of severity criteria
170. An audit of the assessment and management of adults admitted to Christchurch Hospital with community acquired pneumonia
171. Predicting death in patients hospitalized for community-acquired pneumonia
172. Prognostic analysis and predictive rule for outcome of hospital treated community-acquired pneumonia
173. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis
174. Validation of a pneumonia prognostic index using the MedisGroups Comparative Hospital Database
175. Recurrence of pneumonia in middle-aged and elderly adults after hospital-treated pneumonia: Aetiology and predisposing conditions
176. A prognostic rule for elderly patients admitted with community-acquired pneumonia
177. Community-acquired pneumonia in older patients
178. Community-acquired pneumonia in the elderly: A multivariate analysis of risk and prognostic factors
179. Simplifed prediction rule for prognosis of patients with severe community acquired pneumonia in intensive care units
180. Comparison of a disease-specific and a generic severity of illness measure for patients with community-acquired pneumonia
181. Severe community-acquired pneumonia. Etiology, prognosis, and treatment
182. A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit
183. A prediction rule to identify low-risk patients with community-acquired pneumonia
184. Aetiology, outcome and prognostic factors in community-acquired pneumonia requiring hospitalization
185. Community-acquired pneumonia: Factors influencing intensive care admission
186. Evaluation of a ten-question mental test in the institutionalized elderly
187. Prospective study of epidemiology and prognostic factors in community-acquired pneumonia
188. Community-acquired pneumonia of diverse aetiology: Prognostic features in patients admitted to an intensive care unit and a "severity of illness" core
189. Do pulmonary radiographic findings at presentation predict mortality in patients with community-acquired pneumonia?
190. Risk factors in community-acquired pneumonia: Can they be quantified?
191. Use of guidelines in treating community-acquired pneumonia
192. Safely increasing the proportion of patients with community-acquired pneumonia treated as outpatients: An interventional trial
193. A controlled trial of a critical pathway for treatment of community-acquired pneumonia
194. Risk factors for community-acquired pneumonia diagnosed by general practitioners in the community
195. An investigation into the effects of exercise tolerance training on patients with chronic airways obstruction
196. Prospective study of pneumonia hospitalizations and mortality of U.S. older people: The role of chronic conditions, health behaviors, and nutritional status
197. American College of Chest Physicians/National Heart, Lung, and Blood Institute National Conference on oxygen therapy
198. Acute hypercapnic respiratory failure in patients with chronic obstructive lung disease: Risk factors and use of guidelines for management
199. An investigation into the effectiveness of physiotherapy in the treatment of patients with community acquired pneumonia
200. Bottle-blowing in hospital-treated patients with community-acquired pneumonia
201. Acute respiratory failure in patients with severe community-acquired pneumonia. A prospective randomized evaluation of noninvasive ventilation
202. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis
203. Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia. A randomized controlled study
204. Clostridium difficile: A pathogen of the nineties
205. Antimicrobial associations of an outbreak of diarrhoea due to Clostridium difficile
206. Health care resource utilization and antimicrobial use in elderly patients with community-acquired lower respiratory tract infection who develop Clostridium difficile-associated diarrhoea
207. Prospective study of the risk of Clostridium difficile diarrhoea in elderly patients following treatment with cefotaxime or piperacillin-tazobactam
208. The role of antimicrobial agents in the aetiology of Clostridium difficile-associated disease
209. An antibiotic policy associated with reduced risk of Clostridium difficile-associated diarrhoea
210. Risk factor for Clostridium difficile infection
211. Respiratory antibiotics use and Clostridium difficile infection: Is it the drugs or is it the doctors?
212. Increased incidence of Clostridium difficile infection
213. Sequential intravenous/oral ciprofloxacin compared with parenteral ceftriaxone in the treatment of hospitalised patients with community acquired pneumonia
214. Efficacy and tolerability of a teicoplanin-ciprofloxacin combination in severe community-acquired pneumonia
215. Antimicrobial resistance in Haemophilus influenzae from England and Scotland in 1991
216. Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens: Findings of the Alexander Project 1992-1996
217. A comparison of antimicrobial resistance rates in Gram-positive pathogens isolated in the UK from October 1996 to January 1997 and October 1997 to January 1998
218. Antibiotic resistance among clinically important Gram-positive bacteria in the UK
219. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain
220. Pneumonia caused by penicillin-non-susceptible and penicillin-susceptible pneumococci in adults: A case-control study
221. The clinical relevance of antibiotic resistance in the management of pneumococcal pneumonia
222. Impact of antibiotic resistance on chemotherapy for pneumococcal infections
223. Influence of comorbidity and severity on the clinical outcome of bacteremic pneumococcal pneumonia treated with betalactam monotherapy
224. Comparative validation of prognostic rules for community acquired pneumonia in an elderly population
225. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada
226. Susceptibility of Legionella species to five antibiotics and development of resistance by exposure to erythromycin, ciprofloxacin, and rifampicin
227. Antibiotic penetration in the respiratory tract and implications for the selection of antimicrobial therapy
228. Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract
229. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections
230. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
231. Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials
232. Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection
233. A comparative safety and efficacy study of clarithromycin and erythromycin stearate in community-acquired pneumonia
234. Treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing clarithromycin with erythromycin
235. Randomized double-blind trial of the comparative effecacy and safety of cefpodoxime proxetil and cefaclor in the treatment of acute community-acquired pneumonia
236. Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia
237. Oral versus intravenous antibiotics for community acquired lower respiratory tract infection in a general hospital: Open, randomised controlled trial
238. Ofloxacin versus standard therapy in treatment of community-acquired pneumonia requiring hospitalization
239. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia
240. Sequential therapy with cefuroxime followed by cefuroxime axetil in community-acquired pneumonia
241. Clarithromycin vs combined cefuroxime and erythromycin in the treatment of hospitalized community-acquired pneumonia patients: Intravenous followed by oral therapy
242. Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia
243. Comparative study of levofloxacin and amoxycillin/clavulanic acid in adults with mild-to-moderate community-acquired pneumonia
244. Treatment of community-acquired pneumonia in outpatients: Randomized study of clarithromycin alone versus clarithromycin and cefuroxime
245. Sequential intravenous/oral ciprofloxacin compared with parenteral ceftriaxone in the treatment of hospitalized patients with community-acquired pneumonia
246. Multicenter randomized trial comparing meropenem. (1.5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia
247. Tolerance study of ceftriaxone compared with amoxicillin in patients with pneumonia
248. Antibiotic therapy in pneumonia: A comparative study of parenteral and oral administration of penicillin
249. Efficacy and tolerance of cefpodoxime proxetil compared with ceftriaxone in vulnerable patients with bronchopneumonia
250. Comparative study of clarithromycin and roxithromycin in the treatment of community-acquired pneumonia
251. Adult response to initial treatment with ampicillin in community acquired pneumonia in Yaounde, Cameroon
252. Penicillin G/ofloxacin versus erythromycin/amoxicillin-clavulanate in the treatment of severe community-acquired pneumonia
253. A prospective open-label multicentre trial on the use of 1g, once daily ceftriaxone in lower respiratory tract infections
254. Efficacy of a three-day course of azithromycin in the treatment of community-acquired pneumococcal pneumonia. Preliminary report
255. A randomized comparative study on the safety and efficacy of clarithromycin and erythromycin in treating community-acquired pneumonia
256. Efficacy of a three day course of azithromycin in moderately severe community-acquired pneumonia
257. Cefuroxime compared to amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia
258. A prospective randomized study of inpatient iv. antibiotics for community-acquired pneumonia. The optimal duration of therapy
259. Clarithromycin versus amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia
260. Hospitalized patients with community-acquired pneumonia in Hong Kong: A randomized study comparing imipenem/cilastatin and ceftazidime
261. Current usefulness of procaine penicillin in the treatment of pneumococcal pneumonia
262. Once a day levofloxacin in the treatment of mild to moderate and severe community-acquired pneumonia in adults
263. The clinical benefit of in-hospital observation in 'low-risk' pneumonia patients after conversion from parenteral to oral antimicrobial therapy
264. Efficacy, safety, and tolerance of piperacillin/tazobactam compared ro co-amoxiclav plus an aminoglycoside in the treatment of severe pneumonia
265. Ceforamide and cefazolin therapy of pneumonia: Comparative clinical trial
266. Single-blind controlled study of ceftizoxime and cefamandole in the treatment of community-acquired pneumonia
267. Comparative trial of cefonicid and cefamandole in the therapy of community-acquired pneumonia
268. Ceftazidime and cefamandole in the treatment of pneumonia
269. Comparison of cefonicid and cefamandole for the treatment of community-acquired infections of the lower respiratory tract
270. Ampicillin versus cefamandole as initial therapy for community-acquired pneumonia
271. Efficacy and safety of temafloxacin versus those of amoxicillin in hospitalized adults with community-acquired pneumonia
272. Cefetamet pivoxil in community-acquired pneumonia: An overview
273. Twice daily dosing of erythromycin acistrate in the treatment of acute bronchitis and pneumonia
274. The effectiveness and safety of ceftriaxone to cefetamet pivoxil vs ceftazidime to cefetamet pivoxil vs cefoperazone to cefetamet pivoxil in the treatment of community-acquired pneumonia in adult filipinos
275. A comparative study of dirithromycin and erythromycin in bacterial pneumonia
276. Randomized comparative trial with ampicillin/sulbactam versus cefamandole in the therapy of community acquired pneumonia
277. Single daily dose of cefodizime in patients with community-acquired pneumonia: An open-label, controlled, randomized study
278. Five-day azithromycin in the treatment of patients with community-acquired pneumonia
279. Sparfloxacin for the treatment of community-acquired pneumonia: A pooled data analysis of two studies
280. Clinical efficacy of dirithromycin in patients with bacteremic pneumonia
281. Oral empiric treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin
282. Comparative efficacy of sparfloxacin in comparison with amoxycillin plus ofloxacin in the treatment of community-acquired pneumonia
283. Safety profile of sparfloxacin in the treatment of respiratory tract infections
284. Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: A randomized, double-masked, comparative, multicenter study
285. Comparison of cefdinir and cefaclor in treatment of community-acquired pneumonia
286. Atypical pneumonia in the Nordic countries: Aetiology and clinical results of a trial comparing fleroxacin and doxycycline
287. Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia
288. Once-daily sparfloxacin versus high-dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults
289. Comparison of roxithromycin with cefixime in the treatment of adults with community-acquired pneumonia
290. Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia
291. Cefepime versus ceftriaxone for empiric treatment of hospitalized patients with community-acquired pneumonia
292. Trovafloxacin vs high dose amoxicillin in the treatment of community-acquired bacterial pneumonia
293. Oral trovafloxacin compared with amoxicillin (plus optional erythromycin) for the treatment of mild to moderate community-acquired pneumonia
294. Treatment of community-acquired pneumonia in the elderly: The role of cefepime, a fourth-generation cephalosporin
295. A multicenter study of grepafloxacin and clarithromycin in the treatment of patients with community-acquired pneumonia
296. Oral trovafloxacin vs oral cefuroxime +/- erythromycin in community-acquired pneumonia
297. Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia
298. Efficacy and safety of moxifloxacin vs clarithromycin for community-acquired pneumonia
299. Comparison of cefadroxil and cephalexin in the treatment of community-acquired pneumonia
300. Efficacy of clarithromycin against Mycoplasma pneumoniae
301. Efficacy and safety of intravenous cefotaxime for treating pneumonia in outpatients
302. Switch therapy in community-acquired pneumonia
303. Comparison of oral cefuroxime axetil and oral amoxycillin/clavulanate in the treatment of community-acquired pneumonia
304. A comparative study of meropenem and ceftazidime in the treatment of patients hospitalized with community-acquired pneumonia
305. Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia
306. Azithromycin: Single 1.5 g dose in the treatment of patients with atypical pneumonia syndrome: A randomized study
307. Comparative clinical study of cefonicid, chloramphenicol, and penicillin in community-acquired pneumonia
308. Ofloxacin in community-acquired lower respiratory infections. A comparison with amoxicillin or erythromycin
309. Clinical efficacy of azithromycin in lower respiratory tract infections
310. Practical considerations and guidelines for the management of community-acquired pneumonia
311. Infections caused by erythromycin-resistant Streptococcus pneumoniae: Incidence, risk factors, and response to therapy in a prospective study
312. Breakthrough sepsis in macrolide-resistant pneumococcal infection
313. Pneumococcal macrolide resistance: Myth or reality?
314. Pneumococcal macrolide resistance: Not a myth
315. The role of newer macrolides in the treatment of community-acquired respiratory tract infection. A review of experimental and clinical data
316. The next generation: Fluoroquinolones in the management of acute lower respiratory infection in adults
317. Relation between beta-lactamase producing bacteria and patient characteristics in chronic obstructive pulmonary disease (COPD)
318. Quality of care, process, and outcomes in elderly patients with pneumonia
319. A national confidential enquiry into community acquired pneumonia deaths in young adults in England and Wales
320. Susceptibilities of Legionella spp. to newer antimicrobials in vitro
321. Effect of macrolides as part of initial empiric therapy on medical outcomes for hospitalised patients with community acquired pneumonia
322. Antimicrobial chemotherapy for Legionnaires disease: Time for a change
323. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M intracellulare infection
324. Osteomyelitis due to Mycobacterium haemophilum in a cardiac transplant patient: Case report and analysis of interactions among clarithromycin, rifampin, and cyclosporine
325. Levofloxacin in the treatment of community-acquired pneumococcal pneumonia
326. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia
327. Oral administration of antibiotics: A rational alternative to the parenteral route
328. Sequential antibiotic therapy: Effective cost management and patient care
329. Comparison of 7 versus 10 days of antibiotic therapy for hospitalized patients with uncomplicated community-acquired pneumonia: A prospective, randomized, double-blind study
330. Sequential switch therapy for lower respiratory tract infections: A European perspective
331. Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia
332. Management of parapneumonic effusions. An analysis of physician practice patterns
333. A new classification of parapneumonic effusions and empyema
334. Pleural fluid chemical analysis in parapneumonic effusions. A meta-analysis
335. Influenza deaths in Leicestershire during the 1989-90 epidemic: Implications for prevention
336. Reduction in mortality associated with influenza vaccine during 1989-90 epidemic
337. Deaths in Great Britain associated with the influenza epidenic of 1989-90
338. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community
339. Influenza vaccination levels
340. Influenza immunization; vaccine offer, request and uptake in high-risk patients during the 1991/2 season
341. Adverse reactions to influenza vaccine in elderly people: Randomised double blind placebo controlled trial
342. Clinical effectiveness of influenza vaccination in Manitoba
343. Influenza vaccine effectiveness in preventing hospitalization for pneumonia in the elderly
344. Complications of influenza and benefits of vaccination
345. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease
346. The efficacy of influenza vaccination in elderly individuals: A randomized double-blind placebo-controlled trial
347. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature
348. Influenza vaccines: The effect of vaccine dose on antibody response in primed populations during the ongoing interpandemic period. A review of the literature
349. Protection against influenza after annually repeated vaccination: A meta-analysis of serologic and field studies
350. Do hospital employees benefit from the influenza vaccine? A placebo-controlled clinical trial
351. Effectiveness of influenza vaccine in health care professionals: A randomized trial
352. Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly
353. Characterisation of the cassette containing genes for type 3 capsular polysaccharides
354. Potential interventions for the prevention of childhood pneumonia: Geographic and temporal differences in serotype and sero-group distribution of sterile site pneumococcal isolates from children. Implications for vaccine strategies
355. Reactions following administration of influenza vaccine alone or with pneumococcal vaccine to the elderly
356. Antibody response to pneumococcal vaccine in middle-aged and elderly patients recently treated for pneumonia
357. Immunogenicity of pneumococcal revaccination in patients with chronic disease
358. Comparison of pneumococcal polysaccharide and CRM197-conjugated pneumococcal oligosaccharide vaccines in young and elderly adults
359. Efficacy of pneumococcal vaccination in adults: A meta-analysis of randomized controlled trials
360. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease
361. Pneumonia: A clinical or radiographic diagnosis? Etiology and clinical features of lower respiratory tract infection in adults in general practice
362. Etiology of community-acquired pneumonia in out-patients
363. Community-acquired pneumonia: Is there difference in etiology between hospitalized and out-patients?
364. Aetiology of community acquired pneumonia in Valencia, Spain: A multicentre prospective study
365. Epidemiology of community-acquired pneumonia in adults: A population-based study
366. Etiology of community-acquired pneumonia in patients requiring hospitalization
367. Community-acquired pneumonia. Importance of initial noninvasive bacteriologic and radiographic investigations
368. Diagnosis of pneumonia by cultures, bacterial and viral antigen detection tests, and serology with special reference to antibodies against pneumococcal antigens
369. Legionella: An infrequent cause of adult community acquired pneumonia in Dublin
370. Incidence and clinical features of community-acquired legionellosis in hospitalized patients
371. Etiologic study of patients with community-acquired pneumonia
372. Aetiology of community-acquired pneumonia in hospital treated patients
373. Prevalence of legionellosis among adults: A study of community-acquired pneumonia in France
374. Emerging pathogens of community-acquired pneumonia: A two-year prospective study
375. Microbial aetiology of community-acquired pneumonia in hospitalised patients
376. Diagnosis of pneumococcal pneumonia by polymerase chain reaction (PCR) in whole blood: A prospective clinical study
377. Community-acquired pneumonia: Impact of immune status
378. Microbial etiology of acute pneumonia in hospitalized patients
379. A predictive model for the treatment approach to community-acquired pneumonia in patients needing intensive care unit admission
380. Severe community-acquired pneumonia: Factors influencing need of intensive care treatment and prognosis
381. A three-year study of severe community-acquired pneumonia with emphasis on outcome
382. Prognostic factors of pneumonia requiring admission to the intensive care unit
383. A new diagnostic approach to the patient with severe pneumonia
384. Q fever in the Basque Country: 1981-1984
385. The importance of Coxiella burnetii as a cause of pneumonia in Nova Scotia
386. The aetiology of severe community-acquired pneumonia and its impact on initial, empiric, antimicrobial chemotherapy
387. Etiology and diagnosis of pneumonia requiring Intensive Care Unit admission
388. Community acquired pneumonia in north eastern Australia: A hospital based study of Aboriginal and non-Aboriginal patients
389. Community-acquired pneumonia in adults at Srinagarind Hospital
390. Severe community-acquired pneumonia in Singapore